Conmed to exit gastroenterology business
As part of the strategic pivot, Conmed will double down on core markets and drop VIABIL stent rights.
As part of the strategic pivot, Conmed will double down on core markets and drop VIABIL stent rights.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
